Literature DB >> 1517530

Serum tumor necrosis factor activity in inflammatory bowel disease.

M Maeda1, N Watanabe, H Neda, N Yamauchi, T Okamoto, H Sasaki, Y Tsuji, S Akiyama, N Tsuji, Y Niitsu.   

Abstract

Serum tumor necrosis factor (TNF) levels in 33 patients with inflammatory bowel disease (IBD) were measured by using a sensitive enzyme immunoassay. Four of five Crohn's diseases (CD) and nine of twenty eight ulcerative colitis (UC) had elevated levels of serum TNF. In active CD or UC, a greater fraction of patients studied had significantly increased serum TNF levels (3/3 for CD and 8/11 for UC). Production of TNF by peripheral blood monocytes when stimulated by lipopolysaccharide was also increased in these patients and correlated with their serum TNF levels. These results suggest that TNF may have some pathoetiological meaning in IBD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517530     DOI: 10.3109/08923979209005404

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   2.730


  21 in total

1.  In vitro production of TNF-alpha,IL-6 and sIL-2R in Chinese patients with ulcerative colitis.

Authors:  Bing Xia; Hai-Jian Guo; JBA Crusius; Chang-Sheng Deng; SGM Meuwissen; AS Pena
Journal:  World J Gastroenterol       Date:  1998-06       Impact factor: 5.742

2.  Chios mastic treatment of patients with active Crohn's disease.

Authors:  Andriana C Kaliora; Maria G Stathopoulou; John K Triantafillidis; George V Z Dedoussis; Nikolaos K Andrikopoulos
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

3.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

Review 4.  Molecular pathways driving disease-specific alterations of intestinal epithelial cells.

Authors:  Rocío López-Posadas; Markus F Neurath; Imke Atreya
Journal:  Cell Mol Life Sci       Date:  2016-09-13       Impact factor: 9.261

5.  The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.

Authors:  Minoru Nakai; Kaori Sudo; Yasuhiro Yamada; Yasushi Kojima; Tomohiro Kato; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

6.  Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic.

Authors:  Andriana-C Kaliora; Maria-G Stathopoulou; John-K Triantafillidis; George-Vz Dedoussis; Nikolaos-K Andrikopoulos
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

7.  Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids.

Authors:  Martin Trapecar; Catherine Communal; Jason Velazquez; Christian Alexander Maass; Yu-Ja Huang; Kirsten Schneider; Charles W Wright; Vincent Butty; George Eng; Omer Yilmaz; David Trumper; Linda G Griffith
Journal:  Cell Syst       Date:  2020-03-18       Impact factor: 10.304

8.  Induction of Colonic M Cells during Intestinal Inflammation.

Authors:  Kaila M Bennett; Erinn A Parnell; Candice Sanscartier; Sophia Parks; Gang Chen; Meera G Nair; David D Lo
Journal:  Am J Pathol       Date:  2016-03-03       Impact factor: 4.307

9.  High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis.

Authors:  László Bene; George Füst; Béla Fekete; Agota Kovács; Laura Horváth; Zoltán Prohászka; Kata Miklós; Gábor Pálos; Mohamed Daha; Henriette Farkas; Lilian Varga
Journal:  Dig Dis Sci       Date:  2003-06       Impact factor: 3.199

10.  Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease.

Authors:  Christine D Palmer; Farooq Z Rahman; Gavin W Sewell; Afshan Ahmed; Margaret Ashcroft; Stuart L Bloom; Anthony W Segal; Andrew M Smith
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.